Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Vers... (ciated With Menopause The safety anal...)

HOME >> BIOLOGY >> TECHNOLOGY

Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo

Date:10/15/2007

ciated With Menopause

The safety analysis of the 12-week study showed that desvenlafaxine was generally well tolerated when patients started with a lower dose (50 mg/day) and then titrated to 100 mg/day. Nausea was reported by 25 percent of postmenopausal women who received either dose of desvenlafaxine, compared to seven percent in those who received placebo. Overall, adverse events led to discontinuation from the study in 11 percent in the desvenlafaxine dose groups, compared to seven percent of those receiving placebo.

There were few clinically important laboratory and vital sign changes, with no significant differences among treatment groups. Discontinuation symptoms have been generally observed with SNRIs and selective serotonin reuptake inhibitors (SSRIs). In this study, discontinuation symptoms were reported by 51 percent of women taking desvenlafaxine vs. 38 percent with women taking placebo.

Poster 422: Archer D., et al. Desvenlafaxine Succinate, a Novel Serotonin and Norepinephrine Reuptake Inhibitor, Improves Mood and Menopausal Symptoms in Women With Hot Flushes Associated with Menopause

Results from this secondary analysis of the 12-week study showed that desvenlafaxine 100 mg or 150 mg improved total mood disturbance score as measured by the Profile of Mood States (POMS), and climacteric symptoms as measured by the Greene Climacteric Scale (GCS), in postmenopausal women with moderate to severe vasomotor symptoms. Mood and climacteric symptoms were assessed by POMS and GCS, respectively, at baseline and weeks 4 and 12.

About Desvenlafaxine

Wyeth Pharmaceuticals is committed to improving the care of patients and understanding the clinical and safety information about its products. The clinical development program for desvenlafaxine involves thousands of subjects and represents a continued exploration of the molecule's potential utility in multiple conditions.

Important Information

Antidepressants, including
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study

Post Your Comments:

Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Vers...(ciated With Menopause The safety anal...)